EPS Corporation Selects ArisGlobal’s LifeSphere® MultiVigilance
Prominent Japan CRO adopts new safety case processing system to further enhance compliance, automation, and efficiency BOSTON, Dec. 18, 2025 /PRNewswire/ -- ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that EPS Corporation, a leading Japan-based contract research organization (CRO), has selected LifeSphere® MultiVigilance to modernize how it...
VetMew, the AI-powered Pet Health Support App, Officially Launches in North American Market
BOSTON, Dec. 18, 2025 /PRNewswire/ -- VetMew, an AI-powered pet health support application, today announced its official launch in the North American market. The app delivers a groundbreaking tool designed to empower pet owners with immediate, accurate, and personalized AI-driven pet health guidance, directly addressing the region's growing pet care challenges. VetMew is a dedicated pet health support app...
CorestemChemon Advances Toward ALS Stem Cell Commercialization with Regulatory Progress in Korea and NSF-Backed U.S. Expansion
SEOUL, South Korea, Dec. 18, 2025 /PRNewswire/ -- CorestemChemon (KOSDAQ: 166480) is entering a critical late-stage phase in the commercialization of its ALS stem cell therapy, Neuronata-R. The company attributes this momentum to advanced domestic regulatory review in Korea, entry into an NSF-supported regenerative medicine ecosystem in the United States, secured commercialization capital, and a sizable open-market share...
Alphamab Oncology Announces IND Application for Innovative PD-L1/ VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE
SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN027, an independently developed innovative bispecific antibody-drug conjugate (ADC) targeting PD-L1 and VEGFR2, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The Company plans to initiate a clinical...
Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature
SAN FRANCISCO and SUZHOU, China, Dec. 18, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major diseases, announces that the results of two Phase 3 clinical studies of mazdutide, the world's first approved glucagon (GCG)/glucagon-like...
Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims
Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business process more aligned with regulatory requirements HONG KONG, Dec. 18, 2025 /PRNewswire/ -- Cognizant (Nasdaq: CTSH) today announced a strategic collaboration with Bupa Hong Kong, a leading health insurance specialist in Hong Kong, to deliver Cognizant's first AI-driven Business-Process-as-a-Service...
Nabsys and Hitachi Present Electronic Genome Mapping Data at Japanese Society of Human Genetics (JSHG) 2025 Annual Meeting
TOKYO, Dec. 18, 2025 /PRNewswire/ -- Nabsys 2.0, LLC (Nabsys), a pioneer in electronic genome mapping technology, in partnership with Hitachi High-Tech Corporation (HHT) announces the presentation of high resolution structural variation data on the OhmX(™) platform at the Japanese Society of Human Genetics (JSHG) Annual Meeting taking place on December 17-20,...
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets
TOKYO, Dec. 18, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") and Talus Bioscience, Inc. ("Talus Bio") announced today that they entered into a collaboration to discover novel Inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets. By combining Talus Bio's assay technologies for screening for TF and PPI inhibitors in...
Datasea Advances Deployment of an Acoustics + AI-Driven Next-Generation Beauty & Health Intelligence System, Addressing a Multi-Billion-Dollar China Market Opportunity
BEIJING, Dec. 17, 2025 /PRNewswire/ -- Datasea (Beijing) Technology Co., Ltd. ("Datasea"), a subsidiary of Datasea Inc. (NASDAQ: DTSS), today announced a strategic partnership with Shenzhen Yizhimei Technology Co., Ltd. ("Yizhimei"). Datasea will empower Yizhimei with its Acoustics + AI technologies to develop a next-generation Acoustics Digital AI Shampooing Robot and...
Neutrinos Wins AI and Machine Learning Innovation Award at InsurInnovator Connect Vietnam 2025
Award recognizes Neutrinos' contribution to advancing AI adoption across the APAC region NEW YORK and SINGAPORE, Dec. 17, 2025 /PRNewswire/ -- Neutrinos, a leader in AI-powered intelligent automation for insurers, has been recognized with the AI and Machine Learning Innovation Award at the IIC Vietnam Awards 2025. Held in conjunction with...
